Markets:

Overview

News

Currencies

International

Treasuries

Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

32.01 -0.50 (-1.54%)

Official Closing Price Updated: 7:00 PM EST, Jan 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries Limited American Depositary Shares

< Previous 1 2

...

17 18 19 20 21 22 23 24 25

...

31 32 Next >

Oil Output Cut May Tip Global Economy Into Recession, Elon Musk's Starship's First Space Tourist, Alphabet Approves Distribution Of Trump's Truth Social App: Top Stories Thursday, Oct. 13 ↗

October 13, 2022

Reuters

Via Benzinga

FDA Signals Shortage For Teva Pharma's ADHD Drug Due To Manufacturing Delay ↗

October 13, 2022

The FDA said that there was a shortage of Adderall after intermittent manufacturing delays at Teva Pharmaceutical Industries Ltd (NYSE: TEVA).

Via Benzinga

Teva Under Suspicion On Practices To Stave Off Copaxone Competition ↗

October 10, 2022

The European Commission, in an interim view, says Teva Pharmaceutical Industries Ltd (NYSE: TEVA) breached European Union (EU) antitrust rules over practices delaying competition to the multiple...

Via Benzinga

Teva Reaches Agreement With Arkansas to Settle the State’s Price Fixing Claims

October 07, 2022

From Teva Pharmaceutical Industries Limited

Via Business Wire

Teva To Start Nationwide Settlement Of Opioid Lawsuits From Next Year: Report ↗

September 19, 2022

Via Benzinga

Teva's Migraine Treatment Effective In Patients With Co-Morbid Depression ↗

September 08, 2022

Via Benzinga

Teva to Host Conference Call to Discuss Third Quarter 2022 Financial Results at 8 a.m. ET on November 3, 2022

October 06, 2022

From Teva Pharmaceutical Industries Limited

Via Business Wire

Teva Announces Largest-Ever Trial to Collect Information from Patients and Physicians About TD, its Impact and Progression Over Time, and Evaluate Treatment-Related Outcomes

October 06, 2022

From Teva Pharmaceutical Industries Limited

Via Business Wire

Teva Reaches Agreement With Georgia to Settle the State’s Price Fixing Claims

September 30, 2022

From Teva Pharmaceutical Industries Limited

Via Business Wire

European Drug Makers Say Higher Energy Costs Eating Margins: Report ↗

September 27, 2022

Europe's drug makers have warned about stopping manufacturing some cheap generic medicines amid surging electricity costs.

Via Benzinga

Teva Launches Honestly HD Website to Provide People Living With Huntington’s Disease (HD) Information, Inspiration and Resources on HD Chorea

September 26, 2022

From Teva Pharmaceutical Industries Limited

Via Business Wire

Biden Announces $1.5B To Combat US Overdose Epidemic, Support Recovery ↗

September 23, 2022

Via Benzinga

Top Financial Media Stories Monday, September 19: Apple iPhone 14's Glitch With Some Third Party Apps, Tesla Wants To Double Sales In Germany, Ford Working On Smartphone Based Crash Detection Tech And More.. ↗

September 19, 2022

Reuters Volkswagen Eyes Juicy Valuations For Porsche IPO

Via Benzinga

Studies Show Effectiveness of AJOVY®▼ (fremanezumab) for Treatment of Migraine in Patients With Co-morbid Depression

September 08, 2022

From Teva Pharmaceutical Industries Limited

Via Business Wire

CONNECT1 Study Published in Journal of Allergy and Clinical Immunology: In Practice Evaluates the Potential of ProAir® Digihaler® (albuterol sulfate) Inhalation Powder and Digihaler System to Help Improve Asthma Management

September 07, 2022

From Teva Pharmaceutical Industries Limited

Via Business Wire

Teva to Present First Data Set from the CONNECT1 Clinical Trial on ProAir® Digihaler® (albuterol sulfate) Inhalation Powder at the European Respiratory Society (ERS) International Congress 2022

August 29, 2022

From Teva Pharmaceutical Industries Limited

Via Business Wire

European Commission grants marketing authorization for Ranivisio▼®* (ranibizumab), a biosimilar to Lucentis®**, for age-related macular degeneration (AMD) the most common cause of blindness in developed countries

August 29, 2022

From Teva Pharmaceutical Industries Limited

Via Business Wire

Is Sanofi A Buy, Despite Recent Stumbles?

August 19, 2022

Pharmaceuticals are subject to whiplash trade. That's evident with sharp moves lower in Sanofi, GSK and Teva on news about clinical trials and legal actions.

Via MarketBeat

Topics Intellectual Property

This Healthcare Stock Dipped Over 30%; Here Are 83 Biggest Movers From Yesterday ↗

August 18, 2022

Gainers

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

August 17, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Sanofi, Children's Place And Some Other Big Stocks Moving Lower On Wednesday ↗

August 17, 2022

Embark Technology, Inc. (NASDAQ: EMBK) fell 25.1% to $12.40. Embark Technology reported the completion of reverse stock split.

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

August 12, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Volume Surges Spark Turnarounds for These 3 Stocks

August 09, 2022

There are countless historical chart examples of high volume moves that mark the beginning of sustained rallies or slumps. Let’s tune into a few examples.

Via MarketBeat

Topics Lawsuit

Why Blue Water Vaccines Is Trading Higher By Around 80%, Here Are 61 Stocks Moving In Wednesday's Mid-Day Session ↗

August 17, 2022

Gainers Blue Water Vaccines, Inc. (NASDAQ: BWV) shares jumped 79.5% to $4.57 after the company announced it plans to explore the potential development of a novel monkeypox vaccine using its norovirus...

Via Benzinga

Why This Teva Pharmaceuticals Analyst Is Turning Bullish 'The Most Room To Re-Rate' ↗

August 05, 2022

Following Teva Pharmaceutical Industries Ltd.’s (NYSE: TEVA) opioid settlement, the Tel Aviv-Yafo, Israel-based company seems to be making “material progress” in clearing its litigation overhangs.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2022 ↗

August 05, 2022

Upgrades

Via Benzinga

Synaptics To $205? Plus Stifel Cuts Twilio's PT From $200 To This Level ↗

August 05, 2022

Stifel cut the price target for Twilio Inc. (NYSE: TWLO) from $200 to $90. Twilio shares fell 9.6% to $88.75 in pre-market trading.

Via Benzinga

What 4 Analyst Ratings Have To Say About Teva Pharmaceutical Indus ↗

August 02, 2022

Analysts have provided the following ratings for Teva Pharmaceutical Indus (NYSE:TEVA) within the last quarter:

Via Benzinga

Cramer Says This Stock Is Losing Money As 'Too Many Companies Doing The Same Thing' ↗

July 29, 2022

On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended selling Marqeta Inc (NASDAQ: MQ) adding that "too many companies doing the same thing as they are, and they’re losing money."

Via Benzinga

Bausch Health (BHC) Stock Plunges 50% on Patent News ↗

July 28, 2022

With Bausch Health losing a critical patent battle enabling its key drug to suffer generic competition, BHC stock veritably crumbled.

Via InvestorPlace

< Previous 1 2

...

17 18 19 20 21 22 23 24 25

...

31 32 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.